Bayer’s BlueRock Therapeutics establishes European site for cell therapy innovation

Berlin, June 8, 2022 – Bayer AG announced this day that BlueRock Therapeutics LP (BlueRock), a scientific stage biopharmaceutical firm and wholly-owned subsidiary of Bayer AG, has established a singular place for cell treatment innovation on Bayer’s campus in Berlin, Germany. This race comes as portion of the firm’s focused boost approach. Whereas working independently, the group at BlueRock may also assist from the trip of various groups at Bayer to enable the enlargement and acceleration of the firm’s scientific trials to Europe. BlueRock lately closed enrollment for a Phase I scientific trial for BRT-DA01, its fresh cell treatment for treating Parkinson’s disease, and intends to open a world non-interventional leer for Parkinson’s patients within the 2nd half of of 2022. 

“This day’s announcement is a broad step forward in advancing our leadership in cell therapies globally. Establishing a presence for BlueRock in Europe provides the opportunity to fortify our collaboration, with the closing purpose to lift cell therapies with transformational capability,” acknowledged Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Prescribed tablets Division. “We leer forward to seeing BlueRock thrive and dawdle the enlargement of the firm. Collectively we can translate pioneering science into tangible therapies for patients.” 

A multidisciplinary BlueRock group will be field up all over 2022 to produce scientific pattern and operational fortify for Europe, along side chemistry, manufacturing and assist an eye on (CMC). The group will originate greater as the firm’s rising pipeline of modern cell therapies for treating patients with neurological, immunological, cardiovascular and ophthalmic diseases progresses. The co-role of the companies’ groups in Berlin will enable BlueRock to leverage Bayer’s global reach and know-how in areas similar to regulatory affairs, scientific pattern, and commercialization. With the institution of its unique place, BlueRock a good deal broadens its geographical footprint, with presence within the US, Canada, and now Europe.

“We are angry to originate greater our operations to Europe,” acknowledged Seth Ettenberg, President and CEO of BlueRock Therapeutics. “The institution of a set in Europe is a basic milestone in our boost approach that can enable us to lengthen the reach of our advancing pipeline of fresh cell therapies to patients globally.”

Bayer and BlueRock part a commitment to setting up unique therapies to tackle devastating diseases in areas of high unmet clinical need. Since the inception of BlueRock in 2016 by Versant Ventures and Bayer AG, the firm has grown from a pre-scientific open-as much as a scientific-stage firm with sites within the United States, Canada and now Europe. As a foundational element of Bayer’s cell and gene treatment approach, the enlargement of BlueRock’s geographical presence strengthens Bayer’s capabilities in cell therapies and as a driver of most up-to-date applied sciences worldwide. 

Relating to the BRT-DA01 Phase I Trial
The principle purpose of the PhI trial is to assess the safety and tolerability of BRT-DA01 transplantation at one-year put up-transplant. The secondary desires of the trial are to assess the proof of transplanted cell survival and motor outcomes at one- and two-years put up-transplant, to overview continued security and tolerability at two years, and to assess feasibility of transplantation. 

In the United States, the trial became once initiated at Weill Cornell Drugs with Dr. Harini Sarva, M.D. as the Critical Investigator (PI) and first surgical procedures being performed by Dr. Viviane Tabar, Chair of the Department of Neurosurgery at Memorial Sloan Kettering Most cancers Heart. Extra Neurology sites had been added at the University of California, Irvine, below the guidance of Dr. Claire Henchcliffe, M.D., D.Phil., F.A.A.N., F.A.N.A. (PI), and at the University Health Community (UHN), below the guidance of Dr. Lozano, O.C., M.D., Ph.D., F.R.C.S.C., F.R.S.C., F.C.A.H.S. (PI) and Dr. Alfonso Fasano, M.D., PhD., Chair in Neuromodulation and Multi-Disciplinary Care, UHN and UoT. 

More facts about the Phase I trial is on hand at clinicaltrials.gov (NCT#04802733).

As a subsequent step, BlueRock Therapeutics plans to open a world non-interventional leer within the 2nd half of of 2022.

More facts about the non-interventional leer is on hand at clinicaltrials.gov (NCT#05363046).

About Parkinson’s Disease
Parkinson’s disease is a progressive neurodegenerative dysfunction induced by nerve cell hurt within the mind, leading to reduced dopamine ranges. The worsening of motor and non-motor indicators is induced by the loss of dopamine-producing neurons. At analysis, it is estimated that patients contain already lost 60-80% of their dopaminergic neurons. Parkinson’s disease ceaselessly begins with a tremor in a single hand. Other indicators are tension, cramping and slowness of circulation (bradykinesia). In step with the Parkinson’s Foundation, more than 10 million folks worldwide endure from Parkinson’s disease. BRT-DA01 is being clinically evaluated in a subset of patients with Parkinson’s disease, the place weird and wonderful medications are now not any longer utterly efficient.

About Bayer
Bayer is a world endeavor with core competencies within the lifestyles science fields of health care and vitamin. Its merchandise and services and products are designed to assist folks and the planet thrive by supporting efforts to master the major challenges equipped by a rising and getting outdated global inhabitants. Bayer is committed to utilizing sustainable pattern and generating a particular impact with its companies. At the an analogous time, the Crew targets to magnify its incomes vitality and make price thru innovation and boost. The Bayer ticket stands for believe, reliability and quality all over the sphere. In fiscal 2021, the Crew employed round 100,000 folks and had sales of 44.1 billion euros. R&D expenses earlier than special items amounted to 5.3 billion euros. For more facts, plug to www.bayer.com.

About BlueRock Therapeutics
BlueRock Therapeutics is a number one engineered cell treatment firm with a mission to make authentic cellular medicines to reverse devastating diseases, with the imaginative and prescient of making improvements to the human situation. The Company’s cell+gene platform harnesses the vitality of cells to make unique medicines for neurology, cardiology, immunology and ophthalmology indications. BlueRock Therapeutics’ cell differentiation know-how recapitulates the cell’s developmental biology to impress authentic cells, some of that are engineered for additional therapeutic unbiased. Utilizing these cell therapies to interchange broken or degenerated tissue brings the probably to revive lost unbiased. BlueRock Therapeutics became once founded in 2016 by Versant Ventures and Bayer AG and capitalized with notion to be one of many biggest-ever Series A financings in biotech historical previous by Bayer AG (thru its Leaps by Bayer unit) and Versant Ventures. The firm became once utterly got by Bayer in 2019. BlueRock Therapeutics’ custom is defined by the braveness to persist despite the misfortune, the urgency to transform treatment and lift hope, integrity guided by mission, and neighborhood-mindedness with the belief that we’re all portion of one thing greater than ourselves. For more facts, consult with www.bluerocktx.com.